


Supplemental Figures for:
Relationship of HER2 alteration and MSI status in colorectal adenocarcinoma
Qiu Miaozen et al.

Supplementary figure 1


Disease free survival (DFS) in patients with HER2 mutation and amplification (A), patients with MSS and MSI-H (B), MSI-H patients with and without HER2 alteration (C).



Supplementary figure 2.

Progression free survival (PFS) of first-line therapy in patients with HER2 mutation and amplification (A), MSI-H patients with and without HER2 alteration (B).

A



B

